Siglec-15: An Attractive Immunotherapy Target
- PMID: 31806628
- DOI: 10.1158/2159-8290.CD-NB2019-136
Siglec-15: An Attractive Immunotherapy Target
Abstract
Siglec-15, which selectively drives immunosuppression in the tumor microenvironment, has emerged as a viable therapeutic target. In a phase I trial of NC318, a Siglec-15 antibody, encouraging efficacy was seen, including a complete response in non-small cell lung cancer refractory to PD-1 blockade.
©2020 American Association for Cancer Research.
Comment on
-
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy.Nat Med. 2019 Apr;25(4):656-666. doi: 10.1038/s41591-019-0374-x. Epub 2019 Mar 4. Nat Med. 2019. PMID: 30833750 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical